ClinicalTrials.gg
RecruitingNCT07446439Updated Apr 20, 2026

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

A Phase 3 interventional study of Tradipitant and Placebo in Nausea and Vomiting and Obesity, sponsored by Vanda Pharmaceuticals. Recruiting at 10 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 290 studies in Nausea with a site in United States — 29 open to participants now, 32 under way, 8 of them phase 3. Nausea · United States.

Planned enrollment
46th of 260
280 · median 86
Started
2026
with 7 others
Phase 3
40 of 290
5 open now
Primary completion
2026-12
later than 7 of 31 live
Registered
283rd of 290
by date

Among the 290 studies in Nausea with a site in United States, this one is the 46th largest by planned enrollment of the 260 interventional ones that give a count, is one of 8 that started in 2026, is one of 40 in phase 3, reaches primary completion later than 7 of the 31 other live ones, and was the 283rd registered.

Nausea

644 studies on the registry are indexed under Nausea; 85 are open to participants now.

Browse Nausea studies →

Open to participants now

29 of the 290 studies in Nausea with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Nausea studies recruiting now, 21 (41%) set no upper age limit and 19 (37%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 290 studies in Nausea with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.

03

Conditions studied

  • Nausea and Vomiting
  • Obesity

Keywords

  • GLP-1R agonist
  • Semaglutide
  • Nausea
  • Vomiting
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 25 and \< 40 kg/m\^2
  • No serious medical problems or chronic diseases, specifically no type I or type II diabetes

Exclusion criteria

Exclusion Criteria:

  • Another disorder that contributes to gastrointestinal symptoms
  • History of intolerance and/or to NK-1 receptor antagonists
  • History of intolerance and/or hypersensitivity to GLP-1 receptor agonists
  • Exposure to any medication within the past 60 days
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
280 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Group

    Treatment with placebo BID for approximately 2 weeks

    Drug: Placebo

  • Experimental
    Tradipitant Group

    Treatment with tradipitant BID for approximately 2 weeks

    Drug: Tradipitant

Interventions

  • Oral Capsule

    Also known as: Nereus, VLY-686

  • DrugPlacebo

    Oral Capsule

This study also gives Semaglutide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary.

    A questionnaire called the Nausea Vomiting Daily Diary (NV-DD) will be completed once a day, which will be used to collect data for this endpoint. The NV-DD asks participants to record their vomiting frequency in a 24-hour period.

    Time frame: 1 week

Secondary outcomes

  1. Proportion of participants with worst nausea severity score ≥ 3 and at least one vomiting episode over 1 week.

    Nausea and vomiting symptoms will be assessed using the NV-DD. The NV-DD asks participants to rate their nausea symptoms on a Likert scale from 0-5 (0=none, 5= very severe) as well as their vomiting frequency in a 24-hour period.

    Time frame: 1 week

  2. To evaluate the effect of tradipitant relative to placebo on the worst of 7 daily nausea severity scores over 1 week.

    Nausea symptoms will be assessed using the NV-DD. The NV-DD asks participants to rate their nausea symptoms on a Likert scale from 0-5 (0=none, 5= very severe).

    Time frame: 1 week

07

Study locations

3 of 10 sites recruiting
  • Vanda Investigational Site
    Los Angeles, California 90025, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    San Diego, California 92108, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    San Jose, California 95124, United States
    Not yet recruiting
    • Vanda Pharmaceuticals · Contact(202) 734-3400
  • Vanda Investigational Site
    Tampa, Florida 33613, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact(202) 734-3400
  • Vanda Investigational Site
    Hamilton, New Jersey 08690, United States
    Not yet recruiting
    • Vanda Pharmaceuticals · Contact(202) 734-3400
  • Vanda Investigational Site
    New York, New York 10016, United States
    Not yet recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Syosset, New York 11791, United States
    Not yet recruiting
    • Vanda Pharmaceuticals · Contact(202) 734-3400
  • Vanda Investigational Site
    Plano, Texas 75024, United States
    Not yet recruiting
    • Vanda Pharmaceuticals · Contact(202) 734-3400
  • Vanda Investigational Site
    San Antonio, Texas 78215, United States
    Not yet recruiting
    • Vanda Pharmaceuticals · Contact(202) 734-3400
  • Vanda Investigational Site
    Burke, Virginia 22015, United States
    Not yet recruiting
    • Vanda Pharmaceuticals · Contact(202) 734-3400
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 43 phase 3 interventional studies under Nausea, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Mar 3, 2026
StartActual
Mar 27, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07446439
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Mar 27, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Apr 20, 2026

Study contacts

Vanda Pharmaceuticals
Contact
clinicaltrials@vandapharma.com
(202) 734-3400
Vanda Pharmaceuticals Inc.
study director · Vanda Pharmaceuticals Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tradipitant

Start the discussion